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Background: Changes in cell shape and plasticity in cytoskeletal dynamics are critically involved in cell adhesion,
migration, invasion and the overall process of metastasis. Previous work in our laboratory demonstrated that the
synthetic steroid mifepristone inhibited the growth of highly metastatic cancer cells, while simultaneously causing
striking changes in cellular morphology. Here we assessed whether such morphological alterations developed in
response to cytostatic concentrations of mifepristone are reversible or permanent, involve rearrangement of
cytoskeletal proteins, and/or affect the adhesive capacity of the cells.
Methods: Cancer cell lines of the ovary (SKOV-3), breast (MDA-MB-231), prostate (LNCaP), and nervous system
(U87MG) were exposed to cytostatic concentrations of mifepristone and studied by phase-contrast microscopy. The
transient or permanent nature of the cytostasis and morphological changes caused by mifepristone was assessed,
as well as the rearrangement of cytoskeletal proteins. De-adhesion and adhesion assays were utilized to determine
if mifepristone-arrested and morphologically dysregulated cells had abnormal de-adhesion/adhesion dynamics
when compared to vehicle-treated controls.
Results: Mifepristone-treated cells displayed a long, thin, spindle-like shape with boundaries resembling those of
loosely adhered cells. Growth arrest and morphology changes caused by mifepristone were reversible in SKOV-3,
MDA-MB-231 and U87MG, but not in LNCaP cells that instead became senescent. All cancer cell types exposed to
mifepristone displayed greatly increased actin ruffling in association with accelerated de-adhesion from the culture
plate, and delayed adhesion capacity to various extracellular matrix components.
Conclusions: Cytostatic concentrations of mifepristone induced alterations in the cellular structure of a panel of
aggressive, highly metastatic cancer cells of different tissues of origin. Such changes were associated with
re-distribution of actin fibers that mainly form non-adhesive membrane ruffles, leading to dysregulated cellular
adhesion capacity.* Correspondence: Carlos. Telleria@usd.edu
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Originally developed as an anti-glucocorticoid agent in
the 1980s, the synthetic steroid mifepristone was also
found to modulate the progesterone receptor. This un-
expected finding led mifepristone to be rapidly repurposed
for its use for early termination of pregnancy. However,
aside from this most common usage, mifepristone has
been proven effective as a growth inhibitor in endomet-
riosis [1,2], uterine fibroids [3-5], and benign cases of
meningioma [6]. In relation to cancer cell growth, mife-
pristone was shown to have antiproliferative effects in
cervical [7], breast (reviewed in [8]), endometrial [9-12],
ovarian [13-17], gastric [18] and prostate cancer cells [19,20].
In mice with spontaneous lung cancer or leukemia, mife-
pristone improved quality of life and longevity [21,22].
Also, mifepristone given daily to case-study patients with
widely metastatic thymic, renal, colon, or pancreatic can-
cers no longer responding to chemotherapy significantly
improved patient quality of life [23]. As early as 1998, the
suggestion of the use of mifepristone as a therapeutic
option for highly aggressive, metastatic cancers was intro-
duced [24]. However, since then there has been little in-
vestigation pursued in this subject area.
Previous work in our laboratory demonstrated that mife-
pristone: i) arrests the growth of ovarian cancer cells by
inhibiting DNA synthesis and halting progression of the cell
cycle at the G1-S transition [17]; ii) prevents repopulation of
remnant ovarian cancer cells when added after platinum or
platinum/taxane therapies [15,25]; and iii) has growth in-
hibitory effects on various cell types representing aggressive
cancers of the prostate, breast, nervous system, and bone
[26]. Of particular interest in this previous study [26] was
the observation that the cells were not only growth inhib-
ited in response to mifepristone, but that they also displayed
major changes in their morphological features.
Changes in cellular structure are a consequence of the
rearrangement of cytoskeletal proteins, and are critically
involved in adhesion turnover and polarized cell migration
required for the success of the metastatic process [27,28].
In this work we studied whether mifepristone-induced
variations in morphology, while cells undergo cytostasis,
are dependent on the continuous presence of the drug,
and whether there is an association between cytostasis, re-
distribution of filamentous actin (F-actin) and tubulin
filaments, and altered adhesion capacity to extracellular
matrix proteins. We report that mifepristone-induced cytos-
tasis and morphological changes were comparable across a
panel of different cancer cell lines, with cells developing a
thin cytoplasm with neurite-like protrusions. Mifepristone
also impacted the distribution of cytoskeletal actin fibers,
with increased concentrations in membrane ruffles, and of
tubulin filaments mainly allocating to the neurite-like cellu-
lar extensions. These observations were associated with an
overall impairment in the dynamics of the adhesive capacityof the cells manifested by accelerated detachment when the
drug was applied to adherent cells, and impaired attach-
ment of cells that were pre-treated with the drug and then
allowed to adhere to extracellular matrix proteins in drug-
free media. These results provide evidence supporting a
potential role of mifepristone in altering the metastatic
capacity of cancer cells.
Methods
Cell culture and in vitro exposure to mifepristone
The human ovarian carcinoma cell line SKOV-3, the
human breast carcinoma cell line MDA-MB-231, the
human glioblastoma cell line U87MG, and the human
prostate carcinoma cell line LNCaP were obtained from
the American Type Culture Collection (ATCC, Manassas,
VA) and cultured as previously detailed [26]. Treatment of
the cells with mifepristone (Sigma Chemical Company,
St. Louis, MO) used a 20,000 μM stock solution of the
drug in DMSO (Mediatech, Herndon, VA). The maximal
concentration of DMSO in medium was 0.15% (v/v). The
final working concentrations of mifepristone were 23.5 μM
for SKOV-3 cells, 30 μM for MDA-MB-231 cells, 20 μM
for U87MG cells, and 20 μM for LNCaP cells. All cells were
cultured at 37°C in a humidified atmosphere in the pres-
ence of 5% CO2. The human fibroblast cell line WI-38 used
as negative control of cell senescence was obtained from
ATCC and was maintained in DMEM (Mediatech) supple-
mented with 10% FBS (Atlanta Biologicals, Lawrenceville,
GA), 10 mM HEPES, 4 mM L-glutamine (Sigma), 1 mM
sodium pyruvate (Mediatech), 100 IU penicillin (Media-
tech), and 100 μg/ml streptomycin (Mediatech). All cells
were cultured at 37°C in a humidified atmosphere in the
presence of 5% CO2.
Time-course of morphology
Cells were seeded in 6-well plates at a density of 100,000
cells per well and allowed 24 h for attachment. Using previ-
ously established cytostatic doses of mifepristone (SKOV-3:
23.5 μM, MDA-MB-231: 30 μM, U87MG: 20 μM, LNCaP:
20 μM) [26]), treatment was performed for 72 h, during
which morphology changes were assessed by phase con-
trast microscopy. Images of vehicle and mifepristone-
treated cells were taken every 12 h throughout the experi-
mental period using a Zeiss Axiovert M200 inverted
microscope with a phase contrast objective (Carl Zeiss,
Thornwood, NY). Additionally, SKOV-3 cells were grown
in chamber slides at a concentration of 10,000 cells per well
and subjected or not to treatment with mifepristone. At
the end of incubation, the cells were fixed with 4% parafor-
maldehyde (Sigma) and stained with hematoxylin (Sigma).
Reversal of cell proliferation and morphology
In order to determine the long-term effect of mifepristone
treatment, cell morphology was assessed after removal of
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containing media was removed, and media for all cells was
replaced with control media. Phase contrast images were
taken at 0 h, 12 h, 24 h, 48 h, and 72 h after mifepristone
withdrawal to observe cell morphology. In addition to
images taken at each time-point, cell number and viability
were determined using the Guava EasyCyte Mini microca-
pillary cytometer (Guava Technologies, Hayward, CA).
Samples were collected at the beginning of the experi-
ment, for vehicle and mifepristone-treated cells after 72h
of treatment, and at each time-point after treatment
withdrawal. Triplicate wells were trypsinized, the cells
pelleted by centrifugation at 500 g for 5 minutes, and
resuspended in an appropriate volume of PBS. A 1:10 (v/v)
dilution of cell suspension and ViaCount reagent (Guava
Technologies) was prepared for each sample. The data
were acquired and analyzed using the CytoSoft 4.1 soft-
ware (Guava Technologies).
Senescence Associated (SA)-β-galactosidase staining
Using 6-well plates, LNCaP cells were plated at a density
of 50,000 cells per well. Cells were treated with mifepris-
tone for 72 h followed by vehicle for 5 days, or vehicle,
5% charcoal-stripped (CS)-FBS, or 10% CS-FBS media
for 8 days prior to SA-β-galactosidase staining. Cells
were fixed in 0.5% glutaraldehyde at 4°C for 10 min and
then washed three times with PBS. Cells were then incu-
bated for 3 h with 5-bromo-4-chloro-3-indolyl-beta-D-
galactopyranoside (X-gal) staining solution consisting of
1 mg/ml X-gal, 40 mM citric acid/sodium phosphate
(pH 6.0), 5 mM potassium ferricyanide, 5 mM potassium
ferrocyanide, 150 mM NaCl, and 2 mM MgCl2. Follow-
ing incubation, cells were washed briefly with PBS and
stored in 100% methanol for analysis and imaging. Cells
that expressed SA-β-galactosidase were stained blue
when viewed using a Zeiss Axiovert M1-Imager (Carl Zeiss)
microscope. Senescence was quantified as the number of
blue-stained cells per field and expressed as a percent of
total number of cells per field and corrected against a nega-
tive control. The average of 9 fields per well was calculated,
with 3 wells per treatment group. Positive controls for sen-
escence staining were LNCaP cells that had been depleted
of steroids by culture in 5% or 10% CS-FBS media as
reported [29]. The negative control for senescence was a
culture of WI-38 fibroblasts maintained in FBS-containing
media.
Immunocytochemistry
All cell lines were plated in 8-well chamber slides at a dens-
ity of 5,000 cells per well. Cells were allowed to attach for
24 h before treatment began. Wells were treated with ve-
hicle or media containing mifepristone for 72 h at doses tai-
lored to induce cytostasis and morphological changes to
individual cell lines. Following treatment cells were fixedaccording to Waterman-Storer et al. [30] to ensure
stabilization of microtubules. First, cells were prefixed for
5 min in a solution of 1% paraformaldehyde, 0.5% Triton
X-100, prepared in PHEM buffer [60 mM Na PIPES,
25mM Hepes, 10 mM EGTA, 4 mMMgSO4, pH 7.2]. Next,
cells were fixed for 15 min in a solution of 1% paraformal-
dehyde, 0.5% glutaraldehyde, prepared in PHEM. This was
followed by 3 washes with PHEM buffer alone. Finally, any
free aldehydes were blocked by 3 × 5 min incubations with
1 mg/ml sodium borohydride. Cells were rinsed with PBS
multiple times and stored in PBS at 4°C until staining. Fol-
lowing fixation, cells were incubated with a blocking buffer
[PBS, 5% normal goat serum (NGS), 0.1% Triton X-100] for
20 min at room temperature. This was followed by 1 h in-
cubation with 1 μg/ml of anti-bovine α-tubulin, mouse
monoclonal antibody (A-11126, Molecular Probes, Eugene,
OR). Any unbound antibody was removed by 3 x 5 min
washes with washing buffer (PBS, 0.1% Triton X-100). Cells
were then incubated at room temperature for 1 h with
1 μg/ml of Alexa FluorW 488 Goat Anti-Mouse IgG (H + L)
(A-11001, Molecular Probes). From this point onward, cells
were protected from light. The unbound secondary anti-
body was removed with 3 x 5 min washes with washing
buffer. To access F-actin distribution, cells were incubated
with Alexa FluorW 594 phalloidin (Invitrogen, Grand Island,
NY). A 6.6 μM stock solution of Alexa FluorW 594 phal-
loidin was diluted with PBS containing 1% BSA in a 1:40
ratio. Cells were incubated with the phalloidin staining so-
lution for 20 min. Finally, cells were washed multiple times
with PBS and mounted using VectashieldW Hard-Set™
Mounting Medium with DAPI (Vector Laboratories Inc.,
Burlingame, CA). Cover slips were added and slides were
allowed to set at room temperature for 15 min. Slides were
then stored at 4°C, protected from light. Images were taken
using a confocal Olympus FV1000 microscope with
FluoViewW software.
SDS-PAGE and western blotting
Cells were treated with vehicle or mifepristone for 72 h,
after which cultures were trypsinized, stained with trypan
blue, and counted using a hemacytometer. Equal numbers
of viable vehicle and mifepristone-treated cells were then
pelleted, washed twice with PBS, and snap frozen followed
by storage at −80°C. Whole cell extracts were obtained,
protein quantitated, separated by SDS-PAGE, electro-
transferred to PVDF membranes, and then probed for 1 h
at room temperature using primary antibodies against
α-tubulin (A-11126; 1:1,000; Molecular Probes), β-actin
(clone AC-15; 1:10,000; Sigma), or GAPDH (ab94985;
1:8,000; Abcam Inc., Cambridge, MA).
De-adhesion assay
Cells were first grown to 50% confluence in 6-well plates,
and then treated with vehicle or mifepristone-containing
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to 0.025% trypsin/0.265 mM EDTA for 30 sec, 2 min or
4 min. Detached cells were removed with a washing of
PBS. Cells remaining adhered were fixed with 100% metha-
nol, stained with crystal violet, and quantified using bright
field microscopy. Cell adhesion was expressed as percent
of adherent cells for each of the times of exposure relative
to the adhesion measured in a culture not exposed to tryp-
sin (considered to be 100%).
Adhesion assays
The first adhesion assay was performed under sterile condi-
tions using the CytoSelect 48-Well Cell Adhesion Assay
(CBA-070, Cell Biolabs Inc., San Diego, CA). Briefly, the ad-
hesion plates containing various extracellular matrix com-
ponents (fibronectin, collagen I, collagen IV, fibrinogen, or
laminin) were allowed to warm up at room temperature for
10 min. Cell suspensions were then prepared containing
1 × 106 cells per ml in serum-free media with or without
mifepristone; 150 μl of each cell suspension was added to
the appropriate wells and the plates were incubated for 60
min at 37°C in a humidified atmosphere in the presence of
5% CO2. The media was discarded from each well and all
wells were washed 4–5 times with 250 μl PBS. PBS was
removed and 200 μl of the provided cell stain solution was
added to each well. The plates were incubated for 10 min at
room temperature. After incubation, the cell stain solution
was removed and each well was washed 4–5 times with
500 μl of deionized water. The final wash was discarded
and wells were allowed to air dry. Next, 200 μl of provided
extraction solution was added to each well and the plates
were incubated for 10 min on an orbital shaker at room
temperature. Finally, 150 μl of each sample was transferred
to 96-well microtiter plates and the optical density at 540
nm was measured using a Titertek Multiskan MCC/340
Microplate Reader II (Dupont, Labsystems, Finland).
When adhesion to fibronectin was further studied,
cells were cultured in the presence of 20 μM mifepris-
tone for 72 h or left untreated in controls. The cells were
trypsinized and incubated in suspension for 20 min to
allow recovery from trypsinization. Thereafter, 100,000
cells were placed per 35 mm diameter plates that had
been pre-coated with 0.1% fibronectin (Sigma), and were
incubated for various times. Cells were fixed with metha-
nol and stained with crystal violet. Counting was achieved
under a microscope by recording number of adherent
cells per 20 X microscopic field.
Statistical analysis
Data processing and statistical analysis were performed
using GraphPad Prism (GraphPad Prism Software, Inc., San
Diego, CA). All data are represented as means ± SEM, and
statistical significance was defined as P < 0.05. To compare
among experimental groups, one-way ANOVA followed bythe Tukey’s multiple comparison test or two-way ANOVA
followed by the Bonferroni’s multiple comparison test were
used as appropriate. To study significant differences be-
tween two groups, the Student’s t-test was used.
Results
Cytostatic concentrations of mifepristone cause
morphological changes in cancer cell lines of the ovary,
breast, prostate, and nervous system
In a previous study we made the serendipitous observa-
tion that when cancer cells of various tissues of origin
were exposed to concentrations of mifepristone that
inhibited their growth [26], the cells displayed major
changes in shape when compared to untreated growing
cells. In the present work, highly aggressive cell lines
representing cancers of the ovary, breast, prostate, and
nervous system were selected for further analysis. Treat-
ment with a previously tailored cytostatic dose of mife-
pristone for each cell line was administered for a period
of 72 h, and images were taken using phase contrast
microscopy every 12 h. At the end of the incubation
period the number of cells was significantly reduced in
mifepristone-treated wells when compared to their vehicle-
treated counterparts (Figure 1A). The growth inhibitory
effect of mifepristone was confirmed in microscopic images
showing fewer cells present in mifepristone-treated cultures
after 72 h incubation (Figure 1B). Phase contrast views
across the panel of cell lines reveal that mifepristone-
treated cells display a long, thin, spindle-like shape with
boundaries resembling those of cells loosely adhered. The
neurite-like extensions induced by mifepristone appear to
reach out to other cells in the field (Figure 1B). The mor-
phological changes induced by mifepristone began to be
appreciated within 24–48 h of treatment (Additional file
1: Figure S1). Further details of thinning of the cytoplasm
can be clearly appreciated upon hematoxylin staining in
SKOV-3 cells that were exposed to 20 μM mifepristone
for 72 h, when compared to vehicle-treated controls
(Additional file 2: Figure S2). The morphological changes
caused by mifepristone in all cell lines also occurred when
cells were cultured at high density (results not shown).
This confirmed the intrinsic effect of mifepristone on cell
shape, and that observed morphological changes were not
a result of perceived bias, owing to the reduced cellular
densities commonly observed in cultures exposed to
mifepristone as a consequence of the cytostatic effect of
the steroid.
Cellular proliferation and morphological changes are
reversible upon removal of mifepristone in all cell lines
except for LNCaP prostate cancer cells that undergo
cellular senescence
To determine the long-term effect of mifepristone on cell
proliferation and morphology, each cell line was cultured
Figure 1 Cells lines representing cancers of the ovary (SKOV-3), breast (MDA-MB-231), nervous system (U87MG), and prostate (LNCaP)
display distinct morphological changes in response to mifepristone treatment. Equal number of cells were plated and allowed to attach for
24 h. Cells were then exposed to vehicle (VEH)-containing media, or media containing a previously tailored cytostatic dose of mifepristone (MF)
for a period of 72 h. At the end of the experiment the total number of cells was recorded by microcytometric analysis (A) and images were
taken using phase contrast microscopy (B). Cells were exposed to the following cytostatic concentrations of MF: 23.5 μM for SKOV-3, 30 μM for
MDA-MB-231, and 20 μM for U87MG and LNCaP. *p < 0.01 and **p < 0.005 vs. VEH (Student’s t-test). Scale bar = 50 μm.
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after, mifepristone was removed from the cultures and
replaced with media lacking the drug for 5 days. Subse-
quently, cultures were imaged and cell number was deter-
mined every 24 h to monitor for reversal of morphology
and proliferation. While the proliferation of SKOV-3,MDA-MB-231, and U87MG cells remained relatively slow
1–2 days post-treatment, by day 3 after mifepristone with-
drawal, cultures were proliferating at the same rate as cul-
tures never treated with the synthetic steroid (Figure 2A-C
and Figure 3A-C). Of note is that mifepristone pretreated
cultures, when re-growing upon drug withdrawal, did not
Figure 2 Time-course effect of mifepristone withdrawal on cancer cells of the ovary (A), breast (B), prostate (C), and nervous system
(D). Cells were seeded at a density appropriate for exponential growth for each cell line, allowed to adhere for 24 h, and then exposed to the
previously determined cytostatic concentrations of mifepristone for 72 h. Thereafter mifepristone-containing media was replaced with normal
growth media and images were taken using phase contrast microscopy after 0, 24, 48 or 72 h (A-D). Scale bar = 50 μm.
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but returned to a comparable doubling time (Figure 3A-C).
In contrast, release of LNCaP cells from mifepristone treat-
ment did not result in a return to normal proliferation
(Figure 2D). Instead, mifepristone-pretreated LNCaP cul-
tures failed to resume growth and remained with a steady
state cell number through 5 days of normal culture con-
ditions, while vehicle cultures increasingly proliferated
(Figure 3D). Such regrowth was not observed either when
extending the incubation in drug-free media for 9 days
(Additional file 3: Figure S3). While LNCaP mifepristone-
treated cultures did not resume normal proliferation, the
cells did not show signs of lethality either, as indicated by
morphological features (Figure 2D) and viability (Figure 3E)
comparable to those of untreated cells. To determine
whether the lack of growth of LNCaP cells upon re-
moval of mifepristone is consequence of a permanentcell cycle arrest associated with cellular senescence, we
stained mifepristone-pretreated LNCaP cells for SA-β-
galactosidase activity. Results shown in Figure 4A reveal
that while cultures not treated with mifepristone display
low percentage of SA-β-galactosidase positive cells, such
number remarkably increased in cultures under the pres-
ence of mifepristone. The increase in the percentage of
SA-β-galactosidase positive cells induced by mifepristone
was similar to that achieved when LNCaP cells were cul-
tured in steroid-deprived medium, a condition reported to
induce senescence in this cell line (Figure 4B) [29].
Cytostatic doses of mifepristone dysregulate the
cytoskeletal architecture of cancer cells
To further characterize the morphological changes caused
by cytostatic, non-lethal concentrations of mifepristone,
the various cancer cell types were cultured in the presence
Figure 3 Long-term effect of mifepristone on tumor cell lines of the ovary (A), breast (B), nervous system (C), and prostate (D, E). Cells
were seeded at a density appropriate for each cell line, allowed to adhere for 24 h, and then exposed to concentrations of mifepristone (MF)
specific for each cell line for 72 h. Thereafter, triplicate wells were harvested by trypsinization and counted by microcytometry. Remaining wells
were returned to vehicle treatment and monitored for 5 days, during which time triplicate wells were harvested and counted every 24 h. Growth
expressed as number of cells per well are shown for each cell line (A-D). Data points represent the mean ± s.e.m of 3 independent experiments
completed in triplicate. Viability of LNCaP cells was also determined by microcytometric analysis (E).
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of filamentous actin (F-actin) and tubulin filaments con-
tributing to cytoskeletal structure and overall cell morph-
ology were assessed. Figure 5 depicts that mifepristone, in
addition to causing changes in overall cell shape, disrupted
the organization of both actin fibers and tubulin filaments.
Confocal imaging revealed that untreated SKOV-3 cells
possess cortical actin, stress fibers, and cell polarity as
shown by the presence of lamellipodia (Figure 5A, left
panel). Mifepristone caused a remarkable change in cell
shape, loss of cortical actin and stress fibers, and gain of
peripheral membrane ruffles rich in polymerized actin
(Figure 5A, right panel). In U87MG cells, treatment with
mifepristone did not change the distribution of cortical
actin substantially, yet it increased the number of periph-
eral actin ruffles (Figure 5B). MDA-MB-231 breast cancer
cells responded to mifepristone with a remarkable increase
not only of peripheral actin ruffles, but also of circular
dorsal actin ruffles or actin ribbons (Figure 5C). Finally inLNCaP cells, mifepristone, as in the other cancer cell
types, caused an increase in the number of peripheral
actin ruffles (Figure 5D). A commonality in all cancer cells
under the effect of mifepristone was the increase in the
number of membrane actin ruffles (Figure 5E). Tubulin,
which in untreated and polarized cells usually arranges
around the microtubule-organizing center and the Golgi
apparatus [31], was mainly found framing the periphery
of the nuclei in control cells; however, in mifepristone-
treated cells, tubulin accumulated mainly in the long-thin
neurite-like extensions (Figure 5). The complete micro-
scopic fields of the cell cultures from which the images
represented in Figure 5 were obtained, can be observed in
Additional file 4: Figure S4.
To evaluate whether mifepristone was merely dysregu-
lating the distribution of actin and tubulin or changing
their abundance, we assessed the expression levels of
one of the isotypes of actin, β-actin, and one of the iso-
types of tubulin, α-tubulin. Given that actin and tubulin
Figure 4 Mifepristone treatment induces senescence in LNCaP cells. LNCaP cells were seeded at 50,000 cells per well and treated with
mifepristone (MF) for 72 h followed by vehicle (VEH) for 5 days; or vehicle, 5% or 10% charcoal-stripped (CS)-FBS-containing media for 8 days.
SA-β-galactosidase staining was performed as surrogate marker of senescent cells. Relative senescence was quantified as the number of cells
with blue cytoplasm per field and expressed as the percent of total number of cells per field (A, B). Nine fields per well were quantified and
completed in triplicate for each treatment group. All treatment groups were corrected against the background provided by the negative
control, WI-38 cells that do not undergo senescence (data not shown). *** p < 0.0001 vs. VEH (one-way ANOVA followed by Tukey’s post-test).
Scale bar = 50 μm.
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blot studies, we sought to evaluate any differences in their
expression by loading lysates obtained from an equal num-
ber of vehicle or mifepristone-treated cells. Membranes
were immunoblotted for β-actin, α-tubulin, and GAPDH,
which was used as protein loading control. Densitometry
analysis was performed and protein levels expressed as the
ratio of β-Actin/GAPDH (Additional file 5: Figure S5A) or
α-Tubulin/GAPDH (Additional file 5: Figure S5B). Mife-
pristone did not significantly change the expression levels
of either β-actin or α-tubulin in any cell line, suggesting
that the action of mifepristone is limited to dysregulating
the distribution of the proteins and, consequently, the
overall architecture of the cytoskeleton
Effect of mifepristone on cellular de-adhesion and
adhesion dynamics
One commonality in the cancer cells that were treated
with cytostatic doses of mifepristone was the increased
density of membrane actin ruffles along the surface of
the cells (Figure 5). Actin ruffles are sheet-like membrane
protrusions that do not adhere to the substratum and in-
crease in number whenever the adhesion of a cell to thesubstratum is not optimal [32,33]. Consequently, we first
investigated whether cells that are already attached, once
treated with mifepristone, are loosely adhered and, sec-
ondly, whether pre-treatment with mifepristone affected
the adhesion capacity of cells to extracellular matrix-
coated surfaces. To answer the first question, we assessed
the capability of cells to remain attached under treatment
with mifepristone via a cell de-adhesion assay. The cells
were plated at equal densities and treated with mifepris-
tone for 72 h, at which point they were exposed to a very
low concentration of trypsin/EDTA for short periods of
time; these conditions do not allow for the optimal detach-
ment of cells that are well adhered. All cells that detached
from the plate were removed, and those remaining were
fixed, stained, and counted. In all cases, cells pre-treated
with mifepristone, having had they morphology altered,
detached at a significantly faster rate than those untreated.
This effect was seen as early as 30 sec following induction
of de-adhesion in all cell lines (Figure 6A-D). Figure 6E
shows a representative field of U87MG cells remaining
in the plate after 4 min of induction of de-adhesion.
Mifepristone-pretreated cells, which are scarce in the cul-
ture field, still show their thin and elongated neurite-like
Figure 5 Effect of mifepristone on cytoskeletal actin fibers and tubulin filaments. SKOV-3 (A), U87MG (B), MDA-MB-231 (C) or LNCaP
(D) cells were cultured in the presence of vehicle (VEH) or a cytostatic concentration of mifepristone (MF) for 72 h, following which
immunofluorescence was used to visualize the cytoskeletal protein α-tubulin. AlexaFluorW 594 phalloidin was utilized to visualize F-actin and DAPI
to label cell nuclei. Images were taking using confocal microscopy. Scale bar = 50 μm. The inset in panel D represents a cell that was in a
different field within the same image and that denotes the characteristic increase in membrane ruffles induced by MF (for the complete image
see Additional file 4: Figure S4). In A-D, long, thin arrows, cortical actin; short, thin arrows, stress fibers; arrowheads, lamellipodia; short, wide
arrows, membrane ruffles. Panel E represents the quantification of the membrane ruffles in culture for all cell lines studied in response to MF.
Ruffles were counted from confocal microscopy images. We expressed membrane ruffling as number of ruffles counted every 25 cells, after
assessing a minimum of 75 cells and a maximum of 250 cells per experimental group, according to the density of the cell culture. *** p < 0.01 vs.
VEH (Student’s t-test).
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http://www.biomedcentral.com/1471-2407/13/35extensions, a consequence of mifepristone action (Figure 6E,
right panel). In contrast, vehicle-treated cells exposed to the
same de-adhesion conditions as their mifepristone-treated
counterparts, were less sensitive to the mild trypsinization
procedure, and depict normal morphology (Figure 6E,
left panel).To assess whether mifepristone impairs the capacity of
cancer cells to adhere to extracellular matrix, cells were
pre-treated for 72 h with or without a cytostatic concen-
tration of mifepristone, trypsinized, and re-plated in
commercially available plates that had been pre-coated
with an array of extracellular matrix proteins including
Figure 6 Exposure to mifepristone impairs the ability of cancer cells to remain adherent. SKOV-3 (A), LNCaP (B), MDA-MB-231 (C) or
U87MG (D) cells were plated at equal densities and treatment with vehicle (VEH) or mifepristone (MF)-containing media was administered for 72 h.
Cells were then exposed to 0.025% trypsin/0.265 mM EDTA for 0.5, 2, or 4 min. The detached cells were removed, while those remaining adherent
were fixed with 100% methanol and stained with 0.25% crystal violet (as shown in panel E for U87MG cells; 4 min trypsin exposure; 200 X). Stained
cells were then imaged and counted via bright field microscopy. Adherent cells were quantified as a percent of control (0 min trypsin exposure). Data
shown represent the mean ± s.e.m. of 3 independent experiments completed in triplicate. * p < 0.01 vs. VEH; ** p < 0.001 vs. VEH (A-D). Statistical
analysis was done using two-way ANOVA followed by Bonferroni’s post-tests.
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http://www.biomedcentral.com/1471-2407/13/35fibronectin, collagen I, collagen IV, laminin or fibrino-
gen. Cells were allowed 1 h to adhere, except for LNCaP
cells that underwent adhesion for 24 h. Thereafter, the
cells were stained and optical density (OD) was mea-
sured. All cell lines showed different kinetics of adhesion
to the substrates offered, as observed by the different
ranges of OD detected (Figure 7A-D). Mifepristone pre-
treated cells, in all cell lines studied, had diminished ad-
hesion to each one of the surfaces within a particular
time-frame (Figure 7A-D). Data presented in Figure 7
represents one experiment that was repeated three times
with a similar trend, yet we found variability in the overall
adhesion capacity of the cell preparations from one ex-
periment to the next. Consequently we semi-quantitated
the data from three experiments; we defined a strong in-
hibitory effect of mifepristone when there was a decrease
in OD reading of more than 50% as compared to vehicle
treated cells; similarly, a slight inhibitory effect was definedas a 10-50% of OD decrease. Finally, a decrease in OD
reading of less than 10% was considered as no effect. In
all cell lines, either a slight or a strong inhibitory effect
of mifepristone on cell adhesion was observed along
the three independent experiments (Additional file 6:
Table S1).
To confirm the impairment of mifepristone-pretreated
cells to adhere to an extracellular matrix-related protein, an
equal number of either vehicle-pretreated or mifepristone-
pre-treated SKOV-3 cells were incubated at 37°C for
various times (0.5, 1, or 2 h) on plates that had been
pre-coated with fibronectin. Thereafter, the cultures were
washed to remove the non-adherent cells, whereas the
cells that had already attached to the plate at each time
point were fixed with methanol, stained with crystal violet,
and their number was quantified per microscopic field.
The results shown in Figure 7E clearly indicate that
pretreatment with mifepristone significantly delayed the
Figure 7 Mifepristone-pretreated MDA-MB-231 (A), U87MG (B), LNCaP (C), and SKOV-3 (D) cells have delayed adhesion to extracellular
matrix proteins. For all cell lines, treatment with cytostatic concentrations of mifepristone was administered for 72 h prior to plating. After
treatment, cells were trypsinized and re-plated in a pre-coated plate at a density of 100,000 cells per well. FN: fibronectin, Col I: collagen I, Col IV:
collagen IV, LN: Laminin, FG: Fibrinogen. Data shown in A-D represent one experiment that was repeated three times with a similar outcome. In
E, SKOV-3 cells were cultured in the presence of vehicle (VEH) or mifepristone (MF) for 72 h. The cells were trypsinized and placed in plates that
had been pre-coated with 0.1% fibronectin or bovine serum albumin (BSA) used as a negative control of adhesion. Adhesion was quantified as
the number of cells attached per 20 X microscopic field. * p < 0.05 vs. VEH; ** p < 0.01 vs. VEH. Statistical analysis was done using two-way
ANOVA followed by Bonferroni’s post-test. Bright field Images in F are representative of vehicle (VEH) or mifepristone (MF)-pretreated cells
observed after 60 min of incubation (200 X).
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http://www.biomedcentral.com/1471-2407/13/35adherence of SKOV-3 cells to fibronectin. Figure 7F
depicts representative bright field images of vehicle- or
mifepristone-pretreated SKOV-3 cells that had attached
to a fibronectin-coated surface for 60 min; it can be
clearly observed the reduced number of adhered cells that
had been pre-treated with mifepristone (Figure 7, right
panel) when compared to those exposed only to vehicle
(Figure 7, left panel).
Discussion
In this study we observed that, at known cytostatic doses,
mifepristone induced a strikingly similar change in shapeof four highly metastatic and aggressive cancer cell lines.
This included shrinkage of the cell body with long, thin,
neurite-like cellular extensions. Morphology changes were
found to be dependent on time of exposure to the drug,
with confirmed and observable phenotypic changes occur-
ring after 48 h. These alterations were not influenced by
the cellular density of culture, suggesting that mifepristone
has an intrinsic effect upon cellular structure, and that this
change in morphology is not a result of lack of perceived
cell number. In addition, treatment with mifepristone was
not associated with changes in total expression of β-actin
and α-tubulin.
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by blocking the action of progesterone on progesterone
receptors (PR) [34]. In cancer cells expressing high levels
of PR, nanomolar concentrations of mifepristone have
been shown to be sufficient to block cell growth ([8] and
references cited therein). In the present work, in cell lines
not expressing canonical PR [26], we used concentrations
of mifepristone in the micromolar range, higher than
those required to bind PR, suggesting that a different
mechanism not involving classical PR is at work. Such
mechanism, which still needs to be unveiled, may be rele-
vant to target with mifepristone cancers not expressing
standard PR.
Potential mediators of the effect of mifepristone are
the glucocorticoid receptors (GR). It was reported that
mifepristone binds GR when used at concentrations
higher than those needed to bind PR [35]. We previously
addressed that the only commonality among the four
cell lines studied in the present work was the expression
of the beta isoform of the GR (GR-β) [26]. This is of
interest as GR-α is considered the driver of glucocorticoid
effects upon regulation of gene transactivation, whereas
GR-β has been mostly considered a dominant negative
isoform [36]. There are however reports indicating that in
cells forced to express only GR-β, mifepristone was the
only one out of more than 50 steroids capable of binding
the receptor [37] and of regulating the activity of a re-
porter gene [38].
When operating at micromolar concentrations, mife-
pristone has a distinctive effect not shared by other nat-
ural and synthetic steroids. For instance, when used at
equimolar concentrations, mifepristone was a much po-
tent inhibitor of ovarian cancer cell growth than proges-
terone, medroxyprogesterone acetate or levonorgestrel
[17]. Furthermore, equimolar concentrations of the GR
agonist dexamethasone did not inhibit growth when
compared to mifepristone or to two other related anti-
progestins, ORG31710 and CDB2914 [39]. At the concen-
tration utilized, dexamethasone was able to down regulate
the expression of GR-α and GR-β isoforms, whereas the
antiprogestins did not, suggesting that they have different
mechanisms of action despite reaching the cells at micro-
molar levels [39].
Important in studying mifepristone as a possible treat-
ment option in oncology was to address its long-term ef-
fect on the cancer cells. Interestingly, upon removal of
mifepristone following exposure for 3 days, cell morph-
ology and proliferation returned to that of untreated
cells in all cell lines except for the LNCaP prostate can-
cer cells. In these cells, the non-proliferative effect of
mifepristone remained as long as 9 days following treat-
ment removal, suggesting an irreversible growth arrest.
Previous research has shown the propensity of LNCaP
cells to enter irreversible growth arrest and senescencein response, for instance, to treatment with doxorubicin
or to culture in androgen-free media [29,40]. We con-
firmed that LNCaP cells exposed to mifepristone become
senescent upon removal of the drug as indicated by the in-
crease in the activity of perinuclear SA-β-galactosidase.
One possible explanation as to why, from a panel of 4 cells
lines, only LNCaP cells underwent senescence following
mifepristone, relies in the likely induction of the tumor
suppressor gene p16Ink4A. While SKOV-3 and U87MG cell
lines are null for p16Ink4A [41-43], and MDA-MB-231 has
a homozygous deletion of p16Ink4A [44,45], LNCaP cells
retain the p16Ink4A gene [46]. Cells that undergo senes-
cence have been reported to upregulate p16Ink4A [47-49],
and not to regrow in response to overexpression of onco-
genic Ras [50]. The phenomenon of senescence has been
studied both in vitro and in vivo, and pro-senescence ther-
apy has rapidly become a target for cancer treatment [51].
Whereas it was shown that senescence occurs naturally in
benign tumors of melanocytes [52], it was also found that
cellular senescence can be induced in vivo and block, for
example, prostate tumorigenesis [53]. Also, the use of
chemotherapy to induce senescence has been shown to be
successful in mice models, leading to an anti-tumor effect
with a corresponding increase in p16Ink4A [54]. The ability
of mifepristone to induce senescence in p16Ink4A-positive
prostate cancer cells provides yet another rationale for its
potential use as an anti-cancer agent, in particular in cells
carrying wild type versions of the p16Ink4A tumor suppres-
sor gene.
An alternative explanation for the senescence induced
by mifepristone in LNCaP cells is the possible mediation
by androgen receptors (ARs). LNCaP is the only cell line
in the studied cohort that expresses ARs [26], which
have been found able to bind mifepristone [55]. Thus,
the role of both p16 Ink4A as well as ARs in the medi-
ation of mifepristone-induced senescence in LNCaP cells
deserves to be investigated.
Mifepristone likely altered cellular morphology as a
consequence of the dysregulation of the cytoskeletal
structure, which was observed via fluorescent staining of
actin fibers (F-actin) and tubulin filaments; these were
both found to rearrange in response to mifepristone.
Actin fibers were found reorganized to sites located at
the ends of tubulin-rich extensions. As this was seen
multiple times in different directions within individual
cells, there appears to be a loss of cell polarity following
mifepristone treatment. Upon mifepristone treatment,
tubulin filaments were mainly located in the neurite-like
extensions, in contrast to their original localization
throughout the cell body with particular intensity around
the nucleus observed in controls.
F-actin is formed by polymerization of actin molecules
that assemble at different times and locations, depending
upon the extracellular environment [32]. These actin-
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microtubule-based structures, reflecting the complexity
of the dynamics of the cytoskeleton [56]. Among the
actin-based structures are: i) cortical actin, which mostly
defines the shape of the cell; ii) finger-like protrusions
termed filopodia that are adhered in some manner to a
substratum or another cell, and are believed to function
as directional sensors; iii) stress fibers that are contract-
ile actomyosin bundles essential for cell adhesion to the
substratum and for changes in cell morphology during
migration; iv) lamellipodia, which are surface-attached
sheet-like, membrane protrusions with weak adherence,
and observed during cell motility and spreading; and v)
ruffles, which are sheet-like membrane protrusions or
flat membrane folds from the cortical cytoskeleton that
do not attach whatsoever to the extracellular matrix.
Ruffles are formed as a consequence of inefficient integrin-
ligand interaction at the leading edge of lamellipodia and
contain densely packed arrays of thin actin filaments [33].
A high frequency of ruffle formation is usually associated
with low lamellipodia formation and inefficient cell adhe-
sion and migration [33]. We propose that mifepristone
induces the accumulation of membrane ruffles and a re-
duction in lamellipodia, thus destabilizing the formation
of cell substrate adhesions by integrins that connect the
cytoskeleton with the extracellular matrix [57]. Under
mifepristone treatment, the formation of adhesions may
be inefficient because lamellipodia may not have the ap-
propriate anchorage, becoming detached and retracted to-
ward the main cell body, thus forming membrane ruffles.
The behavior of mifepristone-treated cells supports the
data of Born et al. [33], suggesting that high ruffling rates
are indicative of inadequate adhesion, whereas low ruffling
rates are associated with optimal adhesion. While the ma-
jority of nascent adhesions undergo rapid turnover such
that their components can be incorporated into newly
formed adhesion sites, a few mature behind the leading
edge in response to tensile stress and increase in size [58].
Adhesion turnover may be blocked by mifepristone lead-
ing to the accumulation of actin ruffles that mature and
do not adhere to the substratum. We suggest that the
more ruffles, the less surface area mifepristone-treated
cells would have to actually develop the needed focal ad-
hesion complexes to link the cytoskeleton, the integrins
and the extracellular matrix.
We observed that cells under the stress of mifepristone
are easily de-adhered from the extracellular surface than
untreated cells when exposed to a sub-optimal concentra-
tion of trypsin. Because an inverse relationship between
de-adhesion time and cell contractility assessed by trypsin-
induced de-adhesion has been demonstrated [59], by alter-
ing cytoskeletal dynamics, mifepristone may interfere with
the molecular link between the actin cytoskeleton and the
extracellular matrix. In addition, owing to the fact thatchanges in shape and cytoskeletal remodeling are coupled
to the cell cycle machinery governing the G1/S transition
[60-62], it is possible that the cell growth inhibition caused
by mifepristone, which we previously demonstrated to be
associated with G1-S cell cycle arrest, blockage of cyclin
dependent kinase 2 activity, and accumulation of cyclin
dependent kinase inhibitors p27kip1 and p21cip1 [14,17,26],
may be secondary to a primary effect on the cytoskeleton.
Since the survival, movement and invasiveness of can-
cer cells in the organism require great plasticity in the
distribution of F-actin, our data suggest the mifepristone
may interfere with such actin polymerization dynamics,
disturbing the metastatic process. Blocking actin plasti-
city with mifepristone can be therapeutically beneficial
to reduce the seeding at secondary sites by cells that had
detached from a primary tumor.
Microtubules are important to maintain cell shape, play
a key role in the polarized distribution of signals within a
cell, and have been implicated in the asymmetric regula-
tion of adhesion dynamics; in particular, they promote
adhesion disassembly triggering the destabilization first,
and then the detachment of adhesion components. At
the same time, adhesions can be pulled off the substrate
by stress fibers, which contract in response to micro-
tubule depolymerization [27]. We observed a lack of ra-
dial distribution of tubulin filaments from the center of
the cells in response to mifepristone; instead we visualized
an increase of tubulin fibers located in the neurite-like
extensions of the cells where the membrane actin ruffles
became abundant, suggesting a connection between re-
distribution of microtubules and dysregulated adhesion.
Usually an intact microtubule network with dynamic
properties that are asymmetric has the full potential to
coordinate adhesion dynamics in different regions of the
cells, allowing directional migration [27]. Mifepristone
may disrupt this dynamic equilibrium, blocking adhe-
sion dynamics, and, tentatively, migration as well. Fur-
ther studies are necessary to elucidate the relationship
between mifepristone treatment, membrane ruffling,
tubulin rearrangement, and cellular adhesion.Conclusions
The anti-cancer effect of mifepristone manifested in the in-
hibition of cellular growth is related to drastic alternations
in cellular morphology with the formation of neurite-like
protrusions and altered cytoskeletal architecture character-
ized by an increase in membrane F-actin ruffling and con-
centration of tubulin filaments at the neurite-like cellular
extensions. Such effect of mifepristone is associated with
dysregulated cellular adhesion; it is reversible in most cell
lines, except for prostate cancer cells that instead undergo
senescence. Whether or not mifepristone-induced cytosta-
sis, and alterations in cell shape, cytoskeletal structure, and
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ties of cancer cells, warrant further investigations.
Additional files
Additional file 1: Figure S1. Time-course effect of mifepristone on
cancer cells of the ovary (A), breast (B), prostate (C), and nervous system
(D). Cells were seeded at a density appropriate for exponential growth
for each cell line, allowed to adhere for 24 h, and then exposed to a
previously determined cytostatic concentration of mifepristone (MF) for
72 h. Cells that received vehicle for 72 h were used as positive control of
growth (right panel, VEH). Images were taken using phase contrast
microscopy every 12 h and examined for morphological changes. Scale
bar = 50 μm.
Additional file 2: Figure S2. Treatment of SKOV-3 cells with
mifepristone induced inhibition of growth associated with changes in
cell morphology. Cells were cultured in 8-well chamber slides in the
presence of vehicle (VEH) or 20 μM mifepristone (MF) for 4 days. At the
end of the incubation cells were fixed with 4% paraformaldehyde and
stained with hematoxylin. X 400.
Additional file 3: Figure S3. Long-term effect of mifepristone on
LNCaP cells. Cells were seeded, allowed to adhere for 24 h, and then
exposed to a cytostatic concentration of mifepristone (MF) for 72 h.
Thereafter, triplicate wells were harvested by trypsinization and counted
by microcytometry. Remaining wells were returned to vehicle treatment
and monitored after 1, 3, 7, or 9 days for their growth in the absence of
MF and compared against the growth of similar number of cells never
exposed to the steroid.
Additional file 4: Figure S4. Effect of mifepristone on the cellular
distribution of filamentous actin (F-actin) and tubulin. SKOV-3 cells,
U87MG, MDA-MB-231 and LNCaP were cultured in the presence of
vehicle (VEH) or mifepristone (MF) for 72 h, following which
immunocytochemistry was used to visualize the cytoskeletal protein α-
tubulin, AlexaFluor 594W phalloidin was used to visualize filamentous
actin (F-actin), and DAPI to label cell nuclei. Images were taken using
confocal microscopy. Scale bar = 50 μm.
Additional file 5: Figure S5. Expression of β-actin and α-tubulin in
mifepristone-treated cells. Cells were plated and exposed to either
vehicle (VEH) or the cytostatic concentration of mifepristone (MF)
optimized previously for each cell line for 72 h. Following treatment, cells
were subsequently harvested, lysed, and whole-protein extracts,
representing equal numbers of VEH or MF-treated cells were separated
by electrophoresis. Immunoblots were then probed for β-actin and α-
tubulin. GAPDH was included as a loading control. Densitometry analysis
was performed from three different experiments and protein levels
expressed as the ratio of β-actin/GAPDH (A), or α-tubulin/GAPDH (B).
Densitometry graphs represent the mean ± s.e.m.
Additional file 6: Table S1. Semi-quantitative representation of the
effect of mifepristone on the adhesion of cells to individual extracellular
matrix proteins.
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